Cargando…

A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer

Background: We evaluated the efficacy and safety of gemcitabine in combination with erlotinib and S-1 for the treatment of advanced pancreatic cancer. Methods: Chemotherapy-naïve patients with pathologically-proven locally advanced, recurrent, or metastatic pancreatic adenocarcinoma were assessed fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Boram, Kim, Bum Jun, Kim, Hyeong Su, Choi, Dae Ro, Shim, Byoung Yong, Lee, Kyung Hee, Kim, Jin Won, Kim, Jung Han, Song, Hunho, Kim, Jong Hyeok, Park, Choong Kee, Lee, Jung Woo, Kim, Min-Jeong, Zang, Dae Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778528/ https://www.ncbi.nlm.nih.gov/pubmed/33403047 http://dx.doi.org/10.7150/jca.50514

Ejemplares similares

A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer
por: Kim, Sejin, et al.
Publicado: (2022)

Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Kim, Jung Han, et al.
Publicado: (2018)

Correlation of Thyroid Transcription Factor-1 Expression with EGFR Mutations in Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Kim, Hyeong Su, et al.
Publicado: (2019)

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
por: Lim, Sung Hee, et al.
Publicado: (2021)

Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report
por: Choi, Seong Ji, et al.
Publicado: (2016)

The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients
por: Jung, Joo Young, et al.
Publicado: (2014)

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer
por: Kim, Jung Han, et al.
Publicado: (2015)

Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review
por: Kim, Hyeong Su, et al.
Publicado: (2018)

Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis
por: Kim, Hyeong Su, et al.
Publicado: (2019)

Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2021)

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review
por: Kim, Bum Jun, et al.
Publicado: (2017)

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
por: Shin, Sangjin, et al.
Publicado: (2016)

A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients
por: Jang, Geundoo, et al.
Publicado: (2013)

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017)

Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
por: Woo, Sang Myung, et al.
Publicado: (2017)

Novel genes exhibiting DNA methylation alterations in Korean patients with chronic lymphocytic leukaemia: a methyl-CpG-binding domain sequencing study
por: Kim, Miyoung, et al.
Publicado: (2020)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells
por: Han, Na-Kyung, et al.
Publicado: (2016)

The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma
por: Kim, Ho Young, et al.
Publicado: (2015)

Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy
por: Kim, Hong Jun, et al.
Publicado: (2020)

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
por: Yoo, Changhoon, et al.
Publicado: (2018)

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1
por: Jung, Joo Young, et al.
Publicado: (2016)

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
por: Halfdanarson, Thorvardur R., et al.
Publicado: (2019)

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2022)

Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1
por: Kim, Min-Kyoung, et al.
Publicado: (2011)

Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine
por: Kim, Tae Hwan, et al.
Publicado: (2017)

Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer
por: Moon, Do Chang, et al.
Publicado: (2016)

Erlotinib Induced Trichomegaly of the Eyelashes
por: Jeon, Sang-Hoon, et al.
Publicado: (2013)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
por: Jung, Minkyu, et al.
Publicado: (2012)

Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study
por: Kim, Young-Gun, et al.
Publicado: (2018)

Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
por: Chung, Moon Jae, et al.
Publicado: (2018)

Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels
por: Sohn, Sung-Hwa, et al.
Publicado: (2020)

TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Analysis of Factors Associated with the Severity of Acute Pancreatitis according to Etiology
por: Kim, Dae Bum, et al.
Publicado: (2017)

Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
por: Lee, Dae Ho, et al.
Publicado: (2015)

Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
por: Choi, Yoo Jin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bc4dqf8avuiq35biu3ghkumis7